Shared impact on transcriptome for the ORFs PTGIR, NFKB1, SLC39A11 and ZBTB40. by Mohamad Karaky (8910497)

Subjects:

Impact of LPS on PTGIR expression in THP-1. by Mohamad Karaky (8910497)

Subjects:

Numeric data for the graphs in the main and the supporting figures. by Mohamad Karaky (8910497)

Subjects:

Shared impact on transcriptome for the ORFs SLC39A11 and NOD2. by Mohamad Karaky (8910497)

Subjects:

Impact of ZBTB40 expression on S100A8/9 genes expression in THP1. by Mohamad Karaky (8910497)

Subjects:

The impact of different concentrations of PTGIR agonist on CP genes. by Mohamad Karaky (8910497)

Subjects:

Gene expression of PTGIR and PTGER4 in hiPSC monocyte/macrophages derived. by Mohamad Karaky (8910497)

Subjects:

Impact of IBD gene candidate ORFs on the THP-1 transcriptome. by Mohamad Karaky (8910497)

Subjects:

The impact of PTGIR agonist on CP genes at different time. by Mohamad Karaky (8910497)

Subjects:

Effects of VDR silencing on mitochondrial activity. by Marco Consiglio (275917)

The cell surface hydrophobicity of <i>P</i>. <i>putida</i> PSm-originated strains. by Andrio Lahesaare (2220580)

Table_1_Atypical neurological manifestations in anti-IgLON5 disease: a case report.docx by Yun Chen (279569)

“…<p>Anti-IgLON5 disease is a recently discovered autoimmune encephalopathy with sleep disorder as a hallmark in the majority of reported cases. …”

ApoA-I and HDL-3 inhibit leukocyte adhesion to endothelial cells in vitro via a PKC-mediated signaling pathway. by Scott J. Cameron (838315)

Semi-log plot of the number of cities in IT provinces, <i>N</i>_{<i>c</i>,<i>p</i>}; the provinces are ranked according to their decreasing “order of importance”, for vario... by Marcel Ausloos (748325)

Performance statistics on model simulations for river flow during calibration and validation. by Fazlul Karim (7225826)

Subjects:

Comparison between modelled and observed daily and monthly flow. by Fazlul Karim (7225826)

Subjects:

Categorisation of subcatchments into functional units (FUs) based on difference in surface elevation. by Fazlul Karim (7225826)

Subjects:

Effects of conivaptan on brain water content (BWC), blood-brain-barrier (BBB) disruption, plasma and urine sodium and osmolality. by Emil Zeynalov (596088)

“…Following MCAO, Evans Blue (EB) extravasation index (I/C) was increased in vehicle treated mice, and reduced in conivaptan treated mice, naïve, n = 5, vehicle, n = 8, Conivaptan 0.2 mg, n = 8. (C, D) Conivaptan treatment of 0.2 mg resulted in an elevation of plasma sodium and osmolality, and decreased urine sodium and osmolality due to aquaresis. …”

Forest plots describing ORs of the association between low baseline PNI and OS at 1-year(A), 3-year(B), 5-year(C), 8-year(D) and 10-year(E) in breast cancer patients. by Guoming Hu (4377886)

Forest plots describing ORs of the association between reduced baseline PNI and DFS at 1-year (A), 3-year(B), 5-year(C), 8-year(D) and 10-year(E) in breast cancer patients. by Guoming Hu (4377886)